Japan's Nichi-Iko prepping for US biosimilar entry
The major Japanese generics firm Nichi-Iko has signalled its intention to move into the biosimilars sector in the US through the establishment of a new subsidiary in this market.
The major Japanese generics firm Nichi-Iko has signalled its intention to move into the biosimilars sector in the US through the establishment of a new subsidiary in this market.